Ceremorphic opens new life sciences division using AI technology to reduce R&D costs

New division will leverage analog and AI technology on its supercomputing platform to develop new drugs

US-based startup Ceremorphic has announced the formation of a new life sciences division called “Ceremorphic Life Sciences,” which has been established to transform the entire drug discovery and development process.

The new division will have access to Ceremorphic’s own proprietary analog and artificial intelligence (AI) technology platform that will allow its team of biology and chemistry experts to begin developing drugs at a pace unprecedented in the pharmaceutical industry.

With more than 10,000 diseases in the world and only 500 drugs available today, the Ceremorphic Life Sciences platform is the first solution capable of closing that gap by bringing efficiency at each level of the current design pipeline. 

“One new drug today typically requires over 10 years to develop, which can easily cost a pharma company more than $2 billion to bring to market,” said Dr Venkat Mattela, Founder and CEO of Ceremorphic.” In addition to the cost, the drug development throughput and the balance of safety and efficacy is sub-optimal. This is going to change with Ceremorphic Life Sciences new design methodology because we have developed a new platform that can speed every single phase of discovery and development and selectivity at every stage." This type of platform has been long considered the holy grail of drug development and we are making it a reality that can transform the entire pharmaceutical industry for the benefit of all of society.”

The new platform, BioCompDiscoverX, is based on Ceremorphic’s own proprietary patent pending technologies and includes a hardware software solution leveraging its own advanced silicon technology. 

Ceremorphic Life Sciences Division is headquartered in San Jose, CA and leverages engineering resources from Ceremorphic’s state-of-the art design centre in Hyderabad.

Published on : 26th October, 2023